{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:55:19Z","timestamp":1788317719908,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06898-1","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:12:50Z","timestamp":1772590370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study"],"prefix":"10.1007","volume":"105","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez-Larran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"6898_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"6898_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"6898_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jama.2024.25349","volume":"333","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Gangat N, Loscocco GG et al (2025) Essential thrombocythemia: A review. JAMA 333:701\u2013714. https:\/\/doi.org\/10.1001\/jama.2024.25349","journal-title":"JAMA"},{"key":"6898_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia Vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953. https:\/\/doi.org\/10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"},{"key":"6898_CR5","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1038\/bcj.2016.70","volume":"6","author":"IS Tiong","year":"2016","unstructured":"Tiong IS, Casolari DA, Nguyen T et al (2016) Masked polycythaemia Vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia Vera. Blood Cancer J 6:e459. https:\/\/doi.org\/10.1038\/bcj.2016.70","journal-title":"Blood Cancer J"},{"key":"6898_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","volume":"14","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Al-Kali A et al (2024) One thousand patients with essential thrombocythemia: the Mayo clinic experience. Blood Cancer J 14:11. https:\/\/doi.org\/10.1038\/s41408-023-00972-x","journal-title":"Blood Cancer J"},{"key":"6898_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-023-00968-7","volume":"14","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG, Gesullo F, Capecchi G et al (2024) One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J 14:10. https:\/\/doi.org\/10.1038\/s41408-023-00968-7","journal-title":"Blood Cancer J"},{"key":"6898_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-025-01235-7","volume":"15","author":"J Thiele","year":"2025","unstructured":"Thiele J, Kvasnicka HM, Gianelli U et al (2025) Evolution of WHO diagnostic criteria in classical myeloproliferative neoplasms compared with the international consensus classification. Blood Cancer J 15:31. https:\/\/doi.org\/10.1038\/s41408-025-01235-7","journal-title":"Blood Cancer J"},{"key":"6898_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-024-00987-y","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A (2024) Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients. Blood Cancer J 14:17. https:\/\/doi.org\/10.1038\/s41408-024-00987-y","journal-title":"Blood Cancer J"},{"key":"6898_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.23617","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Carobbio A et al (2014) Masked polycythemia Vera diagnosed according to WHO and BCSH classification. Am J Hematol 89:199\u2013202. https:\/\/doi.org\/10.1002\/ajh.23617","journal-title":"Am J Hematol"},{"key":"6898_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajh.23694","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Carobbio A et al (2014) Discriminating between essential thrombocythemia and masked polycythemia Vera in JAK2 mutated patients. Am J Hematol 89:588\u2013590. https:\/\/doi.org\/10.1002\/ajh.23694","journal-title":"Am J Hematol"},{"key":"6898_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/leu.2013.380","volume":"28","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A (2014) Rethinking the diagnostic criteria of polycythemia Vera. Leukemia 28:1191\u20131195. https:\/\/doi.org\/10.1038\/leu.2013.380","journal-title":"Leukemia"},{"key":"6898_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000084673","volume":"113","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Diehl V (2005) Initial (latent) polycythemia Vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 113:213\u2013219. https:\/\/doi.org\/10.1159\/000084673","journal-title":"Acta Haematol"},{"key":"6898_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1309\/6BQ5K8LHVYAKUAF4","volume":"130","author":"U Gianelli","year":"2008","unstructured":"Gianelli U, Iurlo A, Vener C et al (2008) The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the early prepolycythemic phase of polycythemia Vera and essential thrombocythemia. Am J Clin Pathol 130:336\u2013342. https:\/\/doi.org\/10.1309\/6BQ5K8LHVYAKUAF4","journal-title":"Am J Clin Pathol"},{"key":"6898_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12552","volume":"96","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Angona A, Ancochea A et al (2016) Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol 96:83\u201389. https:\/\/doi.org\/10.1111\/ejh.12552","journal-title":"Eur J Haematol"},{"key":"6898_CR16","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ajh.24837","volume":"92","author":"HM Kvasnicka","year":"2017","unstructured":"Kvasnicka HM, Orazi A, Thiele J et al (2017) European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia Vera and differentiation from essential thrombocythemia. Am J Hematol 92:1062\u20131067. https:\/\/doi.org\/10.1002\/ajh.24837","journal-title":"Am J Hematol"},{"key":"6898_CR17","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1002\/ajh.24752","volume":"92","author":"K Misawa","year":"2017","unstructured":"Misawa K, Yasuda H, Araki M et al (2017) The 2016 WHO diagnostic criteria for polycythemia Vera renders an accurate diagnosis to a broader range of patients including masked polycythemia Vera: comparison with the 2008 WHO diagnostic criteria. Am J Hematol 92:E128\u2013E130. https:\/\/doi.org\/10.1002\/ajh.24752","journal-title":"Am J Hematol"},{"key":"6898_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41572-025-00608-3","volume":"11","author":"CN Harrison","year":"2025","unstructured":"Harrison CN, Barbui T, Bose P et al (2025) Polycythaemia Vera. Nat Rev Dis Primers 11:26. https:\/\/doi.org\/10.1038\/s41572-025-00608-3","journal-title":"Nat Rev Dis Primers"},{"key":"6898_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"D Luque Paz","year":"2023","unstructured":"Luque Paz D, Kralovics R, Skoda RC (2023) Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood 141:1909\u20131921. https:\/\/doi.org\/10.1182\/blood.2022017578","journal-title":"Blood"},{"key":"6898_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1126\/science.aay9333","volume":"367","author":"CJ Watson","year":"2020","unstructured":"Watson CJ, Papula AL, Poon GYP et al (2020) The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science 367:1449\u20131454. https:\/\/doi.org\/10.1126\/science.aay9333","journal-title":"Science"},{"key":"6898_CR21","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","volume":"99","author":"C Nielsen","year":"2014","unstructured":"Nielsen C, Bojesen SE, Nordestgaard BG et al (2014) JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 99:1448\u20131455. https:\/\/doi.org\/10.3324\/haematol.2014.107631","journal-title":"Haematologica"},{"key":"6898_CR22","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/cam4.2741","volume":"9","author":"RK Pedersen","year":"2020","unstructured":"Pedersen RK, Andersen M, Knudsen TA et al (2020) Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia Vera and related neoplasms. Cancer Med 9:2039\u20132051. https:\/\/doi.org\/10.1002\/cam4.2741","journal-title":"Cancer Med"},{"key":"6898_CR23","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood 141:1934\u20131942. https:\/\/doi.org\/10.1182\/blood.2022017697","journal-title":"Blood"},{"key":"6898_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","volume":"95","author":"BL Stein","year":"2010","unstructured":"Stein BL, Williams DM, Wang N-Y et al (2010) Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95:1090\u20131097. https:\/\/doi.org\/10.3324\/haematol.2009.014407","journal-title":"Haematologica"},{"key":"6898_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"J-J Kiladjian","year":"2022","unstructured":"Kiladjian J-J, Klade C, Georgiev P et al (2022) Long-term outcomes of polycythemia Vera patients treated with ropeginterferon Alfa-2b. Leukemia 36:1408\u20131411. https:\/\/doi.org\/10.1038\/s41375-022-01528-x","journal-title":"Leukemia"},{"key":"6898_CR26","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood.2025028489","volume":"146","author":"WJ Tapper","year":"2025","unstructured":"Tapper WJ, Dawoud AAZ, Score J et al (2025) Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40. Blood 146:3228\u20133233. https:\/\/doi.org\/10.1182\/blood.2025028489","journal-title":"Blood"},{"key":"6898_CR27","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood.2023023787","volume":"145","author":"G Carre\u00f1o-Tarragona","year":"2025","unstructured":"Carre\u00f1o-Tarragona G, Tiana M, Rouco R et al (2025) The JAK2 46\/1 haplotype influences PD-L1 expression. Blood 145:2196\u20132201. https:\/\/doi.org\/10.1182\/blood.2023023787","journal-title":"Blood"},{"key":"6898_CR28","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/leu.2014.328","volume":"29","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Carobbio A et al (2015) The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. Leukemia 29:992\u2013993. https:\/\/doi.org\/10.1038\/leu.2014.328","journal-title":"Leukemia"},{"key":"6898_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2257.1979.tb00467.x","volume":"1","author":"TC Pearson","year":"1979","unstructured":"Pearson TC, Wetherley-Mein G (1979) The course and complications of idiopathic erythrocytosis. Clin Lab Haematol 1:189\u2013196. https:\/\/doi.org\/10.1111\/j.1365-2257.1979.tb00467.x","journal-title":"Clin Lab Haematol"},{"key":"6898_CR30","first-page":"368","volume":"86","author":"J Thiele","year":"2001","unstructured":"Thiele J, Kvasnicka HM, Zankovich R, Diehl V (2001) The value of bone marrow histology in differentiating between early stage polycythemia Vera and secondary (reactive) polycythemias. Haematologica 86:368\u2013374","journal-title":"Haematologica"},{"key":"6898_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.7326\/0003-4819-139-6-200309160-00009","volume":"139","author":"M Ruggeri","year":"2003","unstructured":"Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F (2003) The rate of progression to polycythemia Vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 139:470\u2013475. https:\/\/doi.org\/10.7326\/0003-4819-139-6-200309160-00009","journal-title":"Ann Intern Med"},{"key":"6898_CR32","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544\u20131551. https:\/\/doi.org\/10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"key":"6898_CR33","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/ajh.27400","volume":"99","author":"P Guglielmelli","year":"2024","unstructured":"Guglielmelli P, Mora B, Gesullo F et al (2024) Clinical impact of mutated JAK2 allele burden reduction in polycythemia Vera and essential thrombocythemia. Am J Hematol 99:1550\u20131559. https:\/\/doi.org\/10.1002\/ajh.27400","journal-title":"Am J Hematol"},{"key":"6898_CR34","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857\u20135859. https:\/\/doi.org\/10.1182\/blood-2011-02-339002","journal-title":"Blood"},{"key":"6898_CR35","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V\u2009>\u2009F mutation in patients with polycythemia Vera or essential thrombocythemia. Blood 110:840\u2013846. https:\/\/doi.org\/10.1182\/blood-2006-12-064287","journal-title":"Blood"},{"key":"6898_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 98:1465\u20131487. https:\/\/doi.org\/10.1002\/ajh.27002","journal-title":"Am J Hematol"},{"key":"6898_CR37","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220\u20132228. https:\/\/doi.org\/10.1182\/blood-2013-11-537167","journal-title":"Blood"},{"key":"6898_CR38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ et al (2018) Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 379:1416\u20131430. https:\/\/doi.org\/10.1056\/NEJMoa1716614","journal-title":"N Engl J Med"},{"key":"6898_CR39","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an international prognostic score of thrombosis in world health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120:5128\u20135133 quiz 5252. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"key":"6898_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T et al (2016) Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol 91:390\u2013394. https:\/\/doi.org\/10.1002\/ajh.24293","journal-title":"Am J Hematol"},{"key":"6898_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ajh.24320","volume":"91","author":"T Barbui","year":"2016","unstructured":"Barbui T (2016) Refining prognostication of thrombosis in ET. Am J Hematol 91:361\u2013363. https:\/\/doi.org\/10.1002\/ajh.24320","journal-title":"Am J Hematol"},{"key":"6898_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","volume":"10","author":"P Guglielmelli","year":"2020","unstructured":"Guglielmelli P, Carobbio A, Rumi E et al (2020) Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J 10:21. https:\/\/doi.org\/10.1038\/s41408-020-0289-2","journal-title":"Blood Cancer J"},{"key":"6898_CR43","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V et al (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5:e369. https:\/\/doi.org\/10.1038\/bcj.2015.94","journal-title":"Blood Cancer J"},{"key":"6898_CR44","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1097\/HS9.0000000000000936","volume":"7","author":"A Alvarez-Larr\u00e1n","year":"2023","unstructured":"Alvarez-Larr\u00e1n A, Cuevas B, Velez P et al (2023) Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish registry of essential thrombocythemia. Hemasphere 7:e936. https:\/\/doi.org\/10.1097\/HS9.0000000000000936","journal-title":"Hemasphere"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06898-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06898-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06898-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:47Z","timestamp":1776405587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06898-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6898"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06898-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients will provide written informed consent. Protocol for this study (NCT07203768) was approved by the relevant institutional review board or ethics committee at each participating institution according to the Declaration of Helsinki and the Good Clinical Practice Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}